Skip to main content

Advertisement

SpringerLink
Log in

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

  • Original Articles
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

We have evaluated the potential usefulness of indium-111 labelled [DTPA-D-Phe1]RC-160, derived from the octapeptide somatostatin analogue RC-160, as a radiopharmaceutical for the in vivo detection of somatostatin receptor-positive tumours. For this purpose111In-and111In-labelled [DTPA-D-Phe1]RC-160 was tested for its biological activity, and applied for somatostatin receptor scintigraphy in vivo to rats bearing the transplantable rat pancreatic tumour CA20948, which expresses somatostatin receptors. We previously described the development of the111In-labelled somatostatin analogue [DTPA-D-Phe1]octreotide and its use in the in vivo visualization of somatostatin receptor-positive tumours in rats and in humans. Like [111In-DTPA-D-Phe1]octreotide, [111In-DTPA-D-Phe1]RC-160 showed uptake in and specific binding in vivo to somatostatin receptor-positive organs and tumours, and the tumours were clearly visualized by gamma camera scintigraphy. However, as compared to [111In-DTPA-D-Phe1]octreotide, blood radioactivity (background) was higher, resulting in a lower tumour to blood (background) ratio. Using this animal model we therefore conclude that [111In-DTPA-DPhe1]RC-160 has no advantage over [111In-DTPA-DPhe1]octreotide as a radiopharmaceutical in the visualization of somatostatin receptors which bind both analogues. However, recent reports suggest the existence of different somatostatin receptor subtypes on some human cancers, which differentially bind RC-160 and not octreotide. These tumours include cancers of the breast, ovary, exocrine pancreas, prostate and colon. [111In-DTPA-D-Phe1]RC-160 might be of interest for future use in such cancer patients as a radiopharmaceutical for imaging somatostatin receptor-positive tumours, which do not bind octreotide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reubi JC, Häcki WH, Lamberts SWJ. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors.J Clin Endocrinol Metab 1987;65:1127–1134.

    Google Scholar 

  2. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG, Lamberts SWJ. Somatostatin receptors in human endocrine tumors.Cancer Res 1987;47:551–558.

    Google Scholar 

  3. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SWJ. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system.Cancer Res 1987;47:5758–5764.

    Google Scholar 

  4. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle samples of carcinoids and islet cell carcinomas.Cancer Res 1990;50:5969–5977.

    Google Scholar 

  5. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris LS, Reubi JC, Lamberts SWJ. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin.Lancet 1989;1:242–244.

    Google Scholar 

  6. Bakker WH, Krenning EP, Breeman WAP, Koper JW, Kooij PPM, Reubi JC, Klijn JG, Visser TJ, Doctor R, Lamberts SWJ. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biological activity, and in vivio application in animals.J Nucl Med 1990;31:1501–1509.

    Google Scholar 

  7. Bakker WH, Krenning EP, Breeman WAP, Kooij PPM, Reubi JC, Koper JW, De Jong M, Lameris JS, Visser TJ, Lamberts SWJ. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism and binding to somatostatin receptor-positive tumors in man.J Nucl Med 1991;32:1184–1189.

    Google Scholar 

  8. Lamberts SWJ, Hofland LJ, van Koetsveld PM, Reubi JC, Bruining HA, Bakker WH, Krenning EP. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic cancers: consequences with regard to diagnosis, localization, and therapy.J Clin Endocrinol Metab 1990;71:566–574.

    Google Scholar 

  9. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP Somatostatin-receptor imaging in the localization of endocrine tumors.N Engl J Med 1990;323:1246–1249.

    Google Scholar 

  10. Becker W, Marienhagen J, Scheubel R, Saptogino A, Bakker WH, Breeman WAP, Wolf F. Octreotide scintigraphy localizes somatostatin receptor-positive islet carcinomas.Eur J Nucl Med 1991;18:924–927.

    Google Scholar 

  11. Faglia G, Bazzoni N, Spada A, Arioso M, Ambrosi B, Spinelli F, Sara R, Bonino C, Lungho F. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([1231] SDZ 204–090).J Clin Endocrinol Metab 1991;73:850–856.

    Google Scholar 

  12. Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, Wass JAH, Besser GM. Pituitary imaging using a labeled somatostatin analogue in acromegaly.Clin Endocrinol 1992;36:147–150.

    Google Scholar 

  13. Bakker WH, Krenning EP, J.-C Reubi, Breeman WAP, Setyono-Han B, de Jong M, Kooy PPM, Bruns C, Vanhagen PM, Marbach P, Visser TJ, Pless J, Lamberts SWJ. In vivo application of [111In-DTPA-D-Phe1]octreotide for detection of somatostatin receptor-positive tumors in rats.Life Sci 1991;49:1593–1601.

    Google Scholar 

  14. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, VanHagen PM, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]octreotide in man: metabolism, dosimetry and comparison with [123I-Tyr3]octreotide.J Nucl Med 1992;33:652–658.

    Google Scholar 

  15. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oci HY, VanHagen M, de Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–731.

    Google Scholar 

  16. Bomanji J, Mather S, Ur E, Grossman A, Besser GM, Britton KE. Imaging somatostatin receptor-positive neoplasms with123I Tyr3-octreotide (TOCT) and111In [DTPA-D-Phe1]-octreotide (DOCT) somatostatin analogues.J Nucl Med 1992;33:914.

    Google Scholar 

  17. Pauwels S, Jamar F, Leners N, Fiasse R. Indium-111-pentatreotide scintigraphy in detection of primary, recurrent and metastatic gastro-entero-pancreatic (GEP) endocrine tumors.J Nucl Med 1992;33:976.

    Google Scholar 

  18. Ivancevic V, Nauck C, Sandrock D, Kögler A, Munz DL, Creutzfeldt W, Emrich D. Somatostatin receptor scintigraphy with111In-pentatreotide in gastroenteropancreatic endocrine tumors (GEP).Eur J Nucl Med 1992;19:736.

    Google Scholar 

  19. Van Dongen A, Verhoeff NPLG, Bemelman F, Van Royen EA. Somatostatin receptor imaging with111In-pentatreotide for whole body studies and high resolution brain SPECT.Eur J Nucl Med 1992;19:679.

    Google Scholar 

  20. Joseph K, Stapp J, Reinecke J, Höffken H, Benning R, Neuhaus C, Trautmann ME, Schwerk WB, Arnold R. Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren.Dtsch Med Wochenschr 1992;117:1025–1028.

    Google Scholar 

  21. Srkalovic G, Cai R-Z, Schally AV. Evaluation of receptors for somatostatin in various tumors using different analogs.J Clin Endocrinol Metab 1990;70:661–669.

    Google Scholar 

  22. Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.Proc Natl Acad Sci USA 1989;86:2003–2007.

    Google Scholar 

  23. Pinski J, Milovanovic TY, Hamaoui A, Radulovic S, Cai R-Z, Schally AV. Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin receptors.Proc Soc Exp Biol Med 1992;200:49–56.

    Google Scholar 

  24. Poston GJ, Davis N, Schally AV, Schally AM, Gatiaburu J, Guillou PJ. Phase one B study of somatostatin receptor analogue RC-160 in treatment of patients with advanced exocrine pancreatic tumors.Digestion 1990;46:170.

    Google Scholar 

  25. Poston GJ, Schally AV, Schally AM, Guillou PJ. Phase one study on the use and tolerance of somatostatin receptor analogue RC-160 in the treatment of patients with advanced exocrine pancreatic tumors.Gut 1991;32:A342-A344.

    Google Scholar 

  26. Reubi JC, Horrisberger U, Essed CE, Jeekel J, Klijn JGM, Lamberts SWJ. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas.Gastroenterology 1988;95:760–763.

    Google Scholar 

  27. Maurer R, Reubi JC. Somatostatin receptors in the adrenal.Mol Cell Endocrinol 1986;45:81–90.

    Google Scholar 

  28. Banks WA, Schally AV, Barrera CM, Fasold BM, Durham DA, Csernus VA, Groot K, Ksatin A. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin.Proc Natl Acad Sci USA 1990;87:6762–6766.

    Google Scholar 

  29. Banks WA, Kastin AJ, Radulovic S, Conley FK, Johnson DL, Schally AV. Selective uptake of the somatostatin analog RC-160 across the blood-brain barrier of mice with KHT sarcomas.Anticancer Drugs 1992;3:519–523.

    Google Scholar 

  30. Breeman WAP, Holland LJ, Bakker WH, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Kwekkeboom DJ, Visser TJ, Lamberts SWJ, Krenning EP. Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide.Eur J Nucl Med 1993;20:1089–1095.

    Google Scholar 

  31. Reubi JC. New specific radioligand for one subpopulation of brain somatostatin receptors.Life Sci 1985;36:1829–1836.

    Google Scholar 

  32. Reubi JC, Häcki WH, Lamberts SWJ. Hormone-producing gastrointestinal tumors contain high density of somatostatin receptors.J Clin Endocrinol Metab 1986;63:433–438.

    Google Scholar 

  33. Bakker WH, Albert R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP, [111In-DTPA-D-Phe1]octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabelling and in vitro validation.Life Sci 1991;49:1583–1591.

    Google Scholar 

  34. Hofland LJ, van Koetsveld PM, Verleun TM, Lamberts SWJ. Long-term culture of rat mammatrope and somatrope subpopulations separated on continuous Percoll density gradients: effects of dopamine, TRH, GHRH, and somatostatin.Acta Endocrinol 1990;122:127–136.

    Google Scholar 

  35. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SWJ. Dissociation of antiproliferative and antihormonal effects of somatostatin analog octreotide on 7315b pituitary tumor cells.Endocrinology 1992;131(2):571–577.

    Google Scholar 

  36. Snedecor GW, Cochran WG.Statistical methods,7th edn. Ames, USA: Iowa State University Press, 1980.

    Google Scholar 

  37. Holland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SWJ. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.Endocrinology 1994;134:301–306.

    Google Scholar 

  38. De Jong M, Bakker WH, Bernard HF, Breeman WAP, Visser TJ, Krenning EP. Handling of somatostatin analogues by the perfused rat liver. No intestinal absorption of intact octreotide in vivo in the rat. J Nucl Med 1993:34:165P.

Download references

Author information

Author notes

  1. W. A. P. Breeman

    Present address: Department of Nuclear Medicine, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands

    W. A. P. Breeman, M. van der Pluijm, M. de Jong, W. H. Bakker, D. J. Kwekkeboom & E. P. Krenning

  2. Department of Nuclear Medicine III, University Hospital Dijkzigt, Dr Molewaterplein 40, NL-3015 GD, Rotterdam, The Netherlands

    L. J. Hofland, P. M. van Koetsveld, T. J. Visser, S. W. J. Lamberts & E. P. Krenning

  3. Dr. Daniël den Hoed Cancer Centre, Rotterdam, The Netherlands

    B. Setyono-Han

Authors
  1. W. A. P. Breeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. J. Hofland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. van der Pluijm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. M. van Koetsveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Setyono-Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. H. Bakker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. J. Kwekkeboom
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T. J. Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. W. J. Lamberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. P. Krenning
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breeman, W.A.P., Hofland, L.J., van der Pluijm, M. et al. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide. Eur J Nucl Med 21, 328–335 (1994). https://doi.org/10.1007/BF00947968

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00947968

Key words

Search

Navigation